Last reviewed · How we verify
scopolamine HBr
Scopolamine HBr is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea.
Scopolamine HBr is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea. Used for Motion sickness prevention, Nausea and vomiting (potentially in phase 3 context).
At a glance
| Generic name | scopolamine HBr |
|---|---|
| Sponsor | Repurposed Therapeutics, Inc. |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Scopolamine is a tropane alkaloid that competitively antagonizes muscarinic acetylcholine receptors in the central and peripheral nervous system. By blocking these receptors, it reduces parasympathetic activity, thereby decreasing salivary and gastric secretions and suppressing signals from the vestibular system that trigger nausea and vomiting. This mechanism makes it effective for motion sickness and potentially other conditions involving excessive secretions or vestibular dysfunction.
Approved indications
- Motion sickness prevention
- Nausea and vomiting (potentially in phase 3 context)
Common side effects
- Dry mouth
- Drowsiness
- Blurred vision
- Dizziness
- Urinary retention
Key clinical trials
- Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion (PHASE3)
- Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion (PHASE3)
- Scopolamine in Healthy Volunteers (PHASE1)
- Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness (PHASE3)
- Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- scopolamine HBr CI brief — competitive landscape report
- scopolamine HBr updates RSS · CI watch RSS
- Repurposed Therapeutics, Inc. portfolio CI